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Summary
The distinction between pathogen elim-
ination and damage limitation during
infection is beginning to change perspec-
tives on infectious disease control, and has
recently led to the development of novel
therapies that focus on reducing the illness
caused by pathogens (‘‘damage limitation’’)
rather than reducing pathogen burdens
directly (‘‘pathogen elimination’’). While
beneficial at the individual host level, the
population consequences of these interven-
tions remain unclear. To address this issue,
we present a simple conceptual framework
for damage limitation during infection that
distinguishes between therapies that are
either host-centric (pro-tolerance) or path-
ogen-centric (anti-virulence). We then draw
on recent developments from the evolu-
tionary ecology of disease tolerance to
highlight some potential epidemiological
and evolutionary responses of pathogens to
medical interventions that target the symp-
toms of infection. Just as pathogens are
known to evolve in response to antimicro-
bial and vaccination therapies, we caution
that claims of ‘‘evolution-proof’’ anti-viru-
lence interventions may be premature, and
further, that in infections where virulence
and transmission are linked, reducing
illness without reducing pathogen burden
could have non-trivial epidemiological and
evolutionary consequences that require
careful examination.
Two Ways of Surviving
Infection
When organisms become infected, there
are two ways to minimize virulence (here
defined as damage leading to morbidity or
mortality). One way is to eliminate
pathogens directly. An additional way is
using mechanisms that, while not reducing
pathogen loads directly, reduce the dam-
age caused by their growth (Box 1;
Figure 1) [1–3]. Treating infectious disease
has often taken the road of pathogen
elimination, either by administering anti-
microbial drugs or by stimulating host
immune responses with vaccination to
achieve the same goal. There are, howev-
er, demonstrated drawbacks to pathogen
elimination [4–8]. Notably, one uninten-
tional and very undesirable side-effect of
interventions that kill pathogens is that
they impose strong selection for faster
growing, and/or more resistant pathogens;
when elimination therapies are imperfect
or incomplete, they also leave behind the
few pathogens that are the most capable of
avoiding them [4–8].
To circumvent the drawbacks of path-
ogen elimination, and generate more
sustainable treatments of infection, an
increasingly popular view is to focus less
on pathogen control and more on damage
limitation during infection [9–12]. Instead
of eliminating pathogens, novel therapeu-
tics are focusing on alternative ways of
disarming pathogens, such as interfering
with quorum-sensing and secretion sys-
tems, inhibiting toxin production and
diffusion, and limiting the efficiency of
bacterial adhesion mechanisms (Box 2;
Figure 2; also see Table 1 in [13]). One
particular motivation for this suggestion is
the belief that, by not targeting the
pathogen directly, these approaches will
not select for pathogen resistance strategies
(as is seen in the case of conventional
drugs) or increased pathogen virulence
[13–15]. While this change in direction
seems promising, the truth is we know very
little regarding the potential consequences
of damage limitation therapies for patho-
gen spread and evolution in the long run.
It may be prudent to learn from history, as
once ‘‘fool-proof’’ strategies such as anti-
biotics and vaccines have also been
accompanied by the undesirable outcomes
of multidrug resistant bacteria [16–18]
and vaccine escape variants [7,8]. How-
ever, we may be able to borrow concepts
and approaches from disease evolutionary
ecology, much of which have been devel-
oped in the light of conventional drug
resistance and virulence evolution [19], to
predict likely responses to damage limita-
tion therapies. Below, we outline a simple
framework for considering the epidemio-
logical and evolutionary consequences of
damage limitation during infection. We
highlight the important distinction that
damage limitation, be it via therapeutic
drugs or mechanisms that hosts have
evolved, may be either host- or patho-
gen-centric. We then discuss how this
distinction is useful in understanding some
potential consequences that damage limi-
tation interventions may have for both the
spread of the disease and the evolution of
virulence.
How Can We Limit Damage
during Infection?
Just as hosts have evolved resistance
mechanisms that identify and eliminate
pathogens during infection [20], alternative
natural mechanisms that promote damage
limitation also exist, and may act either on
the host or on the pathogen (Box 2;
Figure 2). These may be classified into
mechanisms that improve host condition
during infection, such that hosts become
more tolerant of infection (‘‘pro-tolerance’’
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mechanisms) [1–3,21], or alternatively
mechanisms that target pathogen-derived
toxins, or that interfere with pathogen
signalling (but importantly that do not
eliminate pathogens), which have been
termed ‘‘anti-virulence’’ mechanisms [10,
14,15]. Given the relative success in
harnessing the power of the immune system
for pathogen elimination (e.g., vaccination),
a logical question is whether we can equally
replicate the damage limitation mecha-
nisms that hosts have evolved to reduce
Figure 1. The effect of damage limitation mechanisms on the loss of host health
during infection. See Box 1 for further details.
doi:10.1371/journal.pbio.1001769.g001
Box 1. The Effect of Damage
Limitation Mechanisms on
Host Disease Tolerance
As pathogen loads increase during
infection, hosts will lose health,
going from a state of no symptoms
to illness and, in extreme cases,
death (Figure 1). Hosts with more
efficient damage limitation are able
to maintain a higher level of health
during infection. These hosts are
able to sustain higher pathogen
loads but experience a less severe
decline in health than less tolerant
hosts. One can imagine several rela-
tionships between increasing path-
ogen load and host health, which
may be infection- or pathogen-
specific (Figure 1). Theory has high-
lighted how the nature of these
specific relationships are important
in determining how pathogens
evolve and spread when host dis-
ease tolerance increases [24]. While
boosting disease tolerance is gen-
erally predicted to lead to an
increase in prevalence, the rate at
which pathogens evolve to grow
and harm their hosts can either
increase or decrease depending on
the shape of the relationship be-
tween host health and pathogen
load [24,30]. The curves drawn in
Figure 1 represent the level of
health experienced by a population
of hosts for a given pathogen load,
in the presence or absence of
damage limitation treatments [24].
To fully grasp the dynamic nature of
damage limitation during infection
it is important to take repeated
measures of host health matched
for pathogen loads. Plotting the
time-ordered behaviour of individ-
ual host health and pathogen loads
has been proposed as a useful
method of describing a range of
alternative trajectories from illness
back to health, which could be
useful to identify options for per-
sonalized anti-infection treatments
[11,57].
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the severity of infectious disease. Many
commonly used anti-inflammatory drugs
already follow this basic principle (Box 2;
Figure 2), because they focus on alleviating
the symptoms of infection without directly
eliminating its cause. More recently, a
novel class of ‘‘anti-virulence’’ drugs has
also emerged [13–15], that reduce patho-
genesis by targeting bacterial compounds
without actually eliminating pathogens
directly (Box 2; Figure 2). These new
approaches seem attractive. First, from
the perspective of the patient, reducing
illness, whether or not killing the cause, is
always the main priority. Second, by not
targeting pathogen growth directly, mech-
anisms that promote damage limitation
have been proposed to reduce selection for
faster growing pathogens, and in principle
temper the evolution of drug resistant or
vaccine escape variants. However, as we
discuss below, unlike pathogen elimination
therapies, the epidemiological and evolu-
tionary consequences of damage limitation
interventions are currently poorly under-
stood and deserve careful attention.
What Are the Consequences of
Damage Limitation for Disease
Spread?
The evolutionary ecology of host disease
tolerance has received significant study
[22–32]. This work can therefore offer
valuable insight into the epidemiological
and evolutionary consequences of thera-
peutics that focus on damage limitation
instead of pathogen elimination, at least
for drugs that promote host disease
tolerance. By definition, tolerant hosts
are able to maintain relatively higher
health as pathogen loads increase during
infection (Box 1; Figure 1) [1–3]. Further-
more, there may be additional benefits in
improving damage limitation: it has been
proposed that by reducing pathogenesis
during infection, anti-virulence drugs
could buy the immune system valuable
time to clear infection [14,15,33], thereby
leading to increased pathogen elimination
Box 2. Mechanisms of Damage Limitation
Host anti-virulence. Some host mechanisms promote milder disease by eliminating pathogen-derived toxins. For example,
it has been shown that cytokine-induced increases in physiological levels of serum lipids may protect animals from
lipopolysaccharide (LPS) toxicity during septic bacterial infection [58,59]. Host serpins have also been found to inhibit bacterial
cysteine-proteases, thereby protecting the host from the virulent effect of infection, without eliminating infection altogether
[60]. These host mechanisms reduce the damage caused during infection by targeting pathogen-derived toxins (that is, they
target virulence) without directly reducing the number of pathogens, resulting in increased host damage limitation (Figure 2).
Host disease tolerance. Other host mechanisms promote tolerance during infection by promoting improved host condition.
For example, host heme oxygenase 1 (HO-1) degrades toxic heme released in the burst of red blood cells during malaria
infections [61–63]. Similarly, the Th2 response has recently been found to reduce pathogenesis during helminthic infection by
both recruiting macrophages to repair tissue damage, and by down-regulating inflammation [64]. These examples underline
how the sources of disease may come from both the infection, and from the host response to the infection [21]. Mechanisms
that help to regulate this response efficiently to reduce immunopathology also follow the functional definition of disease
tolerance, because they increase host health during infection in a way that is independent of pathogen loads (Figure 2) [51].
Pro-tolerance drugs. Beyond host mechanisms, some medical interventions also improve host health without eliminating
pathogens. Common examples include non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen, which
are typically used to reduce pain, inflammation, and stiffness, but do not directly reduce infection burdens (Figure 2) [65].
Anti-virulence drugs. A novel class of drugs that has been proposed to promote damage limitation by interfering with the
causes of virulence without eliminating pathogens [13–15]. Anti-virulence drugs are a class of compounds that are neither
bacteriocidal nor bacteriostatic, but rather reduce virulence by inhibition of bacterial adhesion to host tissues, inhibiting the
secretion of bacterial toxins, or by interfering with the quorum-sensing signalling between bacteria that frequently modulates
virulence factor expression [33,46,47,60,66–72]. Anti-virulence drugs therefore reduce pathogenesis but pathogen loads are not
directly targeted. While this intervention is clearly pathogen-centric (Figure 2), the outcome is analogous to host disease
tolerance because hosts are able to maintain health despite harbouring high infection burdens.
Figure 2. A simple framework for damage limitation. Damage limitation host mechanisms
or drugs may be either host-centric, improving the host’s capacity to tolerate infection, or
pathogen-centric, targeting pathogen derived molecules that promote virulence. In all cases,
damage limitation improves host health without directly eliminating pathogens. See Box 2 for
further details.
doi:10.1371/journal.pbio.1001769.g002
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indirectly. The conditions under which
this may occur are currently unclear, and
so understanding the interplay between
anti-virulence drugs and host immunity
remains an important question to be
addressed. For example, mice experimen-
tally infected with Mycobacterium tuberculosis
and treated exclusively with the common
anti-inflammatory drug ibuprofen showed
reduced lung lesions, and increased bac-
terial clearance and survival relative to
control mice, presumably because of a
reduction in inflammation-related immu-
nopathology [34]. However, a possible
adverse consequence of treatments that
improve host health without eliminating
pathogens is that hosts will present higher
pathogen loads, which may result in more
opportunities for transmission (Figure 3)
[35]. For example, mice with a deficient
cyclooxygenase (COX) pathway, mimick-
ing the effect of COX-2 inhibitor anti-
inflammatory drugs, infected with influen-
za A showed less severe disease symptoms
but had markedly higher lung viral titres
[36]. A similar outcome was found in
murine Trypanosoma cruzi infection, where
treating with a variety of anti-inflamma-
tory cyclooxygenase inhibitors increased
mouse health, but also increased parasit-
aemia relative to control mice [37]. Earlier
work in double-blind clinical trials also
found that treating human rhinovirus
infections with aspirin resulted in elevated
viral shedding rates despite reducing the
severity of other disease symptoms [38].
As a consequence of reducing the
severity of the symptoms of infection, hosts
may therefore show increased potential for
transmission (Figure 3) [1,24,30]. This may
be problematic for two reasons. First, while
treated hosts may be able to tolerate
disease, increased transmission means there
is obvious danger for less tolerant neigh-
bouring populations or migrant hosts that
have not benefitted from the damage
limitation treatment [30]. Second, in the
absence of clear disease symptoms, detec-
tion of infection may be compromised [39],
which could further aid disease spread to
less tolerant hosts. In Box 3 and Figure 4 we
show that the overall effect of damage
limitation therapies on the prevalence of
infection depends on whether anti-viru-
lence drugs target the production of
pathogen virulence factors or simply allevi-
ate their effects (Box 3; Figure 4E and 4F).
For both anti-virulence and pro-tolerance
classes of damage limitation therapies
however, there is a real possibility of
increasing the overall prevalence of infec-
tion, particularly for high efficacy drugs
(Box 3; Figure 4). This scenario may be less
problematic when the symptoms being
targeted are directly responsible for trans-
mission (as in the case of sneezing and
coughing) or if they are the consequence of
an opportunistic or accidental infection, and
therefore present a dead-end to disease
transmission [40]. For other types of infec-
tion however, damage limitation therapies
may have less desirable population-level
effects, which must be carefully considered.
What Are the Consequences of
Damage Limitation for
Pathogen Evolution?
There are two main reasons why we
should care about the effects of damage
limitation on pathogen evolution. One is
the potential for pathogens to evolve
resistance to drugs and vaccines; the other
is the potential for the evolution of
pathogens that cause more virulent infec-
tions. At first glance, the potential effects of
damage limitation on pathogen evolution
might appear desirable: pathogens are not
eliminated, so selection for increased with-
in-host growth rates is reduced, and
therefore the scope of pathogen evolution
under damage limitation therapies has
been proposed to be limited [10,14,15].
However, there is currently little evi-
dence to support this suggestion, and strong
reasons to expect the opposite outcome.
Pro-tolerance and anti-virulence treatment
strategies have a potentially important
difference with regard to the risks of drug
resistance. While they do not eliminate
pathogens, anti-virulence drugs directly
target pathogen phenotypes, and so present
ample opportunities for direct evolutionary
responses to restore a pathogen phenotype
that potentially increases its fitness [41]. For
example, simple changes to pathogen efflux
pump regulation have been shown to
restore virulence expression in the face of
anti-virulence drug treatments [42]. In
contrast, we may expect the host-centric
nature of pro-tolerance drugs to significant-
ly reduce the scope for selection of
resistance mechanisms in pathogens. How-
ever, by changing the level of damage
experienced by an infected host they could
still affect the evolution of virulence. This
may be especially true of infections where
virulence and transmission are linked, via a
trade-off [43]: high levels of transmission
require high levels of within-host growth,
but this may also kill the host prematurely,
resulting in overall lower pathogen trans-
mission. High virulence therefore presents
a cost to the pathogen, whose fitness is
expected to be maximized instead at
intermediate levels of virulence (see
Figure 3. Two roads to health: elimination and damage limitation. During infection,
pathogen growth causes tissue damage that reduces host health (red circle). Health may be
regained through mechanisms that eliminate pathogens (green circle), or instead by mechanisms
that reduce the damage caused by pathogens (yellow circle). Such damage limitation
mechanisms improve health without reducing pathogen burdens, and therefore could result in
hosts being able to tolerate even higher pathogen burdens (scenario 1). Alternatively, reducing
the damage caused by infection could also allow the host immune response to eliminate these
pathogens (scenario 2). It is currently unclear how host mechanisms of pathogen elimination
interact with damage limitation mechanisms.
doi:10.1371/journal.pbio.1001769.g003
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Box 3. Pathogen Evolution in Response to Damage Limitation Therapies
To illustrate how anti-virulence (AV) or pro-tolerance (PT) therapies (Box 2; Figure 2) may affect the evolution of pathogen
virulence we modify the framework presented by Gandon and colleagues [56], which considered the optimal level of pathogen
production of a potentially costly toxin virulence factor (VF) under anti-toxin vaccination. To understand the effect of these
damage limitation therapies on both pathogen evolution and disease spread, we modified this model to incorporate a
weighting factor (k), which determines how much the VF production contributes to transmission:
R0~
b1 azkvð Þb2
szdzazv
" #
:e{cv
where R0 is the pathogen’s basic reproduction number, a proxy for pathogen fitness; b1 is the pathogen baseline transmission
rate; b2 is the exponent of transmission function; d is the baseline host mortality rate; s is the pathogen clearance rate; a is the
baseline (non-toxin) pathogen virulence due to within-host growth; v is the rate of toxin production; and c is the cost of toxin
production. Here we use this simple framework to illustrate how anti-virulence and pro-tolerance damage limitation therapies
influence the pathogen’s optimal rate of VF production, v*, assuming that evolution acts to maximise R0.
Anti-virulence drugs.We first consider the effect of anti-virulence (AV) drugs that act directly on the toxin virulence factor,
reducing its supply, with efficacy r. We call this model the ‘‘AV toxin removal’’ model:
RAV ,10 ~
b1 azk 1{rð Þvð Þb2
szdzaz 1{rð Þv
" #
:e{cv
Note that under AV drug treatment hosts may still suffer from infection due to pathogen growth (a), because AV drugs only
target the virulence factor (VF) component of virulence (v). The above equation assumes the pathogen still makes the toxin and
incurs the cost of producing it, although the toxin is not effective. An alternative may be that the AV drug stops toxin
production. In this case, the AV drug reduces pathogenesis, but also has the collateral effect of alleviating the cost to the
pathogen of producing the toxin. We call this model the ‘‘AV toxin prevention’’ model:
RAV ,20 ~
b1 azk 1{rð Þvð Þb2
szdzaz 1{rð Þv
" #
:e{cv 1{rð Þ
Pro-tolerance drugs. We now consider the effect of pro-tolerance (PT) drugs, which are drugs that alleviate the severity of
disease by targeting host damage without directly affecting pathogen growth rate (Box 2; Figure 2). PT drugs therefore act on
the overall damage caused by the pathogen (a+v), leading to:
RPT0 ~
b1 azkvð Þb2
szdz 1{rð Þ azvð Þ
" #
:e{cv
Evolution of toxin production under the different damage limitation therapies. The specific mechanism of drug
action can have a major impact on the outcome of pathogen evolution: if AV drugs render toxins ineffective but leave the costs
of toxin synthesis intact (‘‘AV toxin removal’’ model; Figure 4A), increasing AV drug efficacy tends to select for increased toxin
production, but will drive toxin production down at very high drug efficacies (to reduce redundant investment costs),
particularly if the link between toxin production and transmission (k) is low. By contrast, if AV drugs act by stopping toxin
production (‘‘AV toxin prevention’’ model; Figure 4B), increasing drug efficacy always selects for pathogen strains that increase
their intrinsic rate of toxin production. PT drugs have a similar effect on pathogen evolution, always selecting for high toxin
production as drug efficacy increases (Figure 4C).
In all scenarios the quantitative level of virulence factor (VF) production depends on how it is related to transmission. When the
disease symptoms that arise from VF production are weakly related to transmission (low k values), the optimal level of toxin
production is lower than when it is strongly linked to transmission, but the effect of k is less important for the PT therapies
(Figure 4C) than the other scenarios explored. Furthermore, very low k values can prevent the escalation of virulence seen
under the AV toxin removal model (Figure 4A), as the continued cost of virulence factor production coupled with a weak
transmission benefit leads to virulence factor investments becoming futile.
In terms of selection for virulence, damage limitation therapies would therefore appear to be more attractive options for the
relief of symptoms that are not directly linked to transmission (low k), compared to symptoms like sneezing or coughing, that
act as catalysts for disease spread. Alternatively, the use of AV drugs that are highly efficient at inactivating toxins (high r) may
be an option, provided pathogens still pay a fitness cost for producing them (Figure 4A and 4B). What is clear is that the
selective effects of damage limitation therapies, regardless of whether they target the host or the pathogen have non-
negligible effects on pathogen evolution.
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[6,44,45] for empirical examples of this
trade-off). Pro-tolerance drugs would allevi-
ate this cost, because pathogens can exploit
hosts more without the risk of host death
becoming too severe. Under this scenario, it
is possible that pro-tolerance interventions
could result in more virulent pathogens.
Indeed, our evolutionary analysis (Box 3)
suggests that selection for increased viru-
lence is a possible outcome of both anti-
virulence and pro-tolerance damage limita-
tion treatments (Box 3; Figure 4A–4C).
Previous theoretical work dealing with
pathogen evolution under variable levels of
disease tolerance suggest that both low and
high virulence evolution is possible depend-
ing on exactly how pathogen within-host
growth impacts host health [24,30]. Em-
pirical tests of these predictions are scarce,
but where available, they suggest caution
in how damage limitation therapies are
applied. For example, quorum-sensing
(QS) signalling in bacteria, which common-
ly induces the expression of virulence
factors, is one of the main targets of current
anti-virulence drugs [46–48]. A recent
study in intubated patients showed that
inhibiting the QS signalling of Pseudomonas
aeruginosa relaxed selection for less virulent
loss-of-function mutants, resulting in the
evolution of more virulent strains during
the course of infection [49]. The reason for
this is that QS loss-of-function mutants are
social cheats; they use the QS signal
produced by the wild-type strain, but do
not pay the cost of producing it. QS loss-of-
function mutants are also less virulent than
the wild type. In the absence of an anti-
virulence drug that blocks QS signalling (in
this case, azithromycin), these cheating
mutants increased in frequency over time
because they don’t pay the fitness cost of
QS signalling. Adding azithromycin signif-
icantly reduced QS-gene expression, and
any advantage of social cheating was lost.
As a result of adding an anti-virulence drug,
selection for lower-virulence mutants was
therefore relaxed, and the more virulent
wild-type isolates increased in frequency.
Interventions that attempt to limit
damage by inhibiting quorum-sensing
dependent virulence factor production
(similar to the ‘‘toxin prevention’’ situation
we model in Box 3) could therefore, in
principle, select for higher virulence. This
outcome is by no means certain and applies
most for infections where pathogen growth
and virulence are highly linked to transmis-
sion; if they are only weakly linked to
transmission (low k in Figure 4) then toxin
removal anti-virulence drugs can select for
reduced virulence (Box 3; Figure 4A). In
other types of infection, for example oppor-
tunistic or accidental pathogens [40], or
when virulence is mainly the consequence of
an over exuberant immune response
[12,50,51], the trade-off hypothesis of viru-
lence evolution will not apply, and damage
limitation therapies may be very promising
in reducing disease severity without the
concern for the effects on disease transmis-
sion or evolution. Generally however, we
currently lack adequate experimental data
to confidently predict the effect of damage
limitation treatments on pathogen evolution.
Perspectives and Outstanding
Questions
Damage limitation presents a promis-
ing alternative to pathogen elimination,
and in some types of infection might be
useful in reducing disease symptoms while
aiding immune clearance. Certainly, it is
important to put these treatments in
context with the available alternatives.
Treating patients is an imperative, yet
among the clinically equivalent options,
we may wish to choose the one that
minimizes the risks of drug resistance and
virulence evolution. Currently, regarding
anti-virulence drugs and other damage
limitation therapies there are important
population-level consequences that re-
main to be fully understood. We focused
on the distinction between pro-tolerance
Consequences of pathogen evolution and drug therapies for pathogen prevalence. We now explore the
population-level epidemiological consequences (infection prevalence) arising from the combination of the above drug
therapies and the consequent evolved virulence levels. To do this we used the following population dynamic framework to
explore how equilibrium pathogen prevalence (P*) varies with efficacy of each drug:
dS
dt
~lH{SIb1 azkvð Þb2e{cv
dI
dt
~SIb1 azkvð Þb2e{cv{I szdzazvð Þ
where S and I are the numbers of susceptible and infected hosts respectively, H ( = S+I) is the total host density and l is the per
capita host growth rate; all other parameters are as defined above. From these equations, the equilibrium pathogen prevalence
is given as:
P~l= szdzazvð Þ
We can then modify this framework to incorporate the different treatment scenarios described above, calculating the
appropriate optimal virulence in each case, and the subsequent consequences for P*. For both the AV toxin removal
(Figure 4D) and PT (Figure 4F) models, increasing drug efficacy initially has little effect on overall infection prevalence of
infection but, at very high drug efficacies, will tend to drive infection prevalence upwards. The population-level prevalence
of infection under the AV toxin prevention drug (Figure 4E) is unaffected by drug efficacy. Overall, combining the results
from the evolutionary and epidemiological analyses suggests that (i) highly effective AV toxin removal drugs can lead to the
evolution of highly prevalent but relatively benign pathogens (Figure 4A and 4D), (ii) highly effective AV toxin prevention
drugs can select for highly pathogenic pathogens of intermediate prevalence (Figure 4B and 4E), and (iii) highly effective PT
drugs provide arguably the worst-case scenario, potentially selecting for highly prevalent and highly virulent pathogens
(Figure 4C and 4F).
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(host-centric) and anti-virulence (patho-
gen-centric) therapies, and we found that
this distinction may be important when
considering the epidemiological and evo-
lutionary consequences of damage limita-
tion interventions (Box 3). In practice,
microbial evolution is rapid and inescap-
able, and a more fruitful approach may
be to use evolution to aid the develop-
ment of better treatments [19]. For
example, it would be especially useful to
test the feasibility of damage limitation
treatments that specifically select for
reduced virulence and resistance, such as
anti-virulence drugs that alleviate symp-
toms that are not strongly linked to
transmission (Box 3; Figure 4A). Here it
may be useful to expand our knowledge of
damage limitation mechanisms from
mammals to other organisms that may
reveal novel mechanisms for damage
limitation therapeutics [52]. Beyond ther-
apeutic measures we would also benefit
from a better understanding of the host
genetic control of damage limitation
mechanisms (Box 2; Figure 2) [3,10].
For example, a better knowledge of pro-
tolerance and anti-virulence mechanisms
may help guide livestock genetic improve-
ment programs, preventing the use of
Figure 4. Epidemiological and evolutionary consequences of damage limitation treatments. Evolutionarily stable virulence factor
production v* (A–C) and prevalence (D–F), plotted against anti-virulence (AV) or pro-tolerance (PT) drug efficacy, r. We plot different levels of how
virulence and transmission are related (k). Model details are described in Box 3. Parameter values are as in [56] b1=1, b2=0.5, d=1, a= 0.2, s=0.1,
c=0.05. Varying the cost of virulence factor production c does not affect the overall trend of the results, although it does affect the magnitude v* and
prevalence.
doi:10.1371/journal.pbio.1001769.g004
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chemicals in the future [53–55]. Theoret-
ical predictions of pathogen evolution
under varying levels of disease tolerance
are also limited [24,30,56], and future
models could be tailored to understand
specific types of host-pathogen interac-
tions. A critical question that is currently
unclear is how damage limitation drugs
might interact with the immune system:
will they simply maintain host health,
buying time to mount a stronger and
more efficient immune response [33]? Or
will tolerant hosts become symptomless,
potentially dangerous carriers of disease
[10,30]? The answer to these questions
will be crucial to the long-term success or
failure of anti-virulence drugs and similar
damage limitation interventions.
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